Molecules 2021, 26, 3944
14 of 14
23. Croft, S.L.; Sundar, S.; Fairlamb, A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19, 111–126. [CrossRef]
24. Field, M.C.; Horn, D.; Fairlamb, A.H.; Ferguson, M.A.J.; Gray, D.W.; Read, K.D.; De Rycker, M.; Torrie, L.S.; Wyatt, P.G.; Wyllie, S.;
et al. Anti-trypanosomatid drug discovery: An ongoing challenge and a continuing need. Nat. Rev. Microbiol. 2017, 15, 217–231.
25. Pérez-Molina, J.A.; Molina, I. Chagas disease. Lancet 2018, 391, 82–94. [CrossRef]
26. Pinazo, M.; Munoz, J.; Posada, E.; Lopez-Chejade, P.; Gallego, M.; Ayala, E.; del Cacho, E.; Soy, D.; Gascon, J. Tolerance of
Benznidazole in treatment of Chagas’ disease in adults. Antimicrob. Agents Chemother. 2020, 54, 4896–4899. [CrossRef] [PubMed]
27. Chatelain, E. Chagas disease research and development: Is there light at the end of the tunnel? Comput. Struct. Biotechnol. J. 2016
,
28. Tarleton, R.L. Chagas Disease: A Solvable Problem, Ignored. Trends Mol. Med. 2016, 22, 835–838. [CrossRef]
˙
29. Gulcan, H.O.; Unlu, S.; Esiringu, I.; Ercetin, T.; Sahin, Y.; Oz, D.; Sahin, M.F. Design, synthesis and biological evaluation of novel
6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors.
30. Sun, W.; Cama, L.D.; Birzin, E.T.; Warrier, S.; Locco, L.; Mosley, R.; Hammond, M.L.; Rohrer, S.P. 6H-Benzo[c]chromen-6-one
derivatives as selective ERβ agonists. Biorgan. Med. Chem. Lett. 2006, 16, 1468–1472. [CrossRef]
31. Appendino, G.; Gibbons, S.; Giana, A.; Pagani, A.; Grassi, G.; Stavri, M.; Smith, E.; Rahman, M.M. Antibacterial Cannabinoids
from Cannabis sativa: A Structure-Activity Study. J. Nat. Prod. 2008, 71, 1427–1430. [CrossRef]
32. Kaplan, B.L.F.; Rockwell, C.E.; Kaminski, N.E. Evidence for Cannabinoid Receptor-Dependent and -Independent Mechanisms of
Action in Leukocytes. J. Pharmacol. Exp. Ther. 2003, 306, 1077–1085. [CrossRef] [PubMed]
33. Munson, A.E.; Harris, L.S.; Friedman, M.A.; Dewey, W.L.; Carchman, R.A. Antineoplastic Activity of Cannabinoids. J. Natl.
Cancer Inst. 1975, 55, 597–602. [CrossRef]
34. Khanolkar, A.D.; Lu, D.; Ibrahim, M.; Duclos, J.R.I.; Thakur, G.A.; Malan, J.T.P.; Porreca, F.; Veerappan, V.; Tian, X.; George, C.;
et al. Cannabilactones: A Novel Class of CB2 Selective Agonists with Peripheral Analgesic Activity. J. Med. Chem. 2007, 50,
35. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365,
36. Thakur, G.A.; Bajaj, S.; Paronis, C.; Peng, Y.; Bowman, A.L.; Barak, L.S.; Caron, M.G.; Parrish, D.; Deschamps, J.R.; Makriyannis, A.
Novel Adamantyl Cannabinoids as CB1 Receptor Probes. J. Med. Chem. 2013, 56, 3904–3921. [CrossRef] [PubMed]
37. Husni, A.S.; McCurdy, C.R.; Radwan, M.M.; Ahmed, S.A.; Slade, D.; Ross, S.A.; ElSohly, M.A.; Cutler, S.J. Evaluation of
Phytocannabinoids from High Potency Cannabis sativa using In Vitro Bioassays to Determine Structure-Activity Relationships
for Cannabinoid Receptor 1 and Cannabinoid Receptor 2. Med. Chem. Res. 2014, 23, 4295–4300. [CrossRef] [PubMed]
38. Mahadevan, A.; Siegel, C.; Martin, B.R.; Abood, M.E.; Beletskaya, I.; Razdan, R.K. Novel Cannabinol Probes for CB1 and CB2
Cannabinoid Receptors. J. Med. Chem. 2000, 43, 3778–3785. [CrossRef] [PubMed]
39. Wilkinson, J.D.; Williamson, E.M. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism
and have a potential therapeutic value in the treatment of psoriasis. J. Dermatol. Sci. 2007, 45, 87–92. [CrossRef]
40. Zygmunt, P.M.; Andersson, D.A.; Hogestatt, E.D. Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive
sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J. Neurosci. 2002, 22, 4720–4727. [CrossRef]
41. Pertwee, R.G. Novel Pharmacological Targets for Cannabinoids. Curr. Neuropharmacol. 2004, 2, 9–29. [CrossRef]
42. Killander, D.; Sterner, O. Synthesis of the Bioactive Benzochromenes Pulchrol and Pulchral, Metabolites of Bourreria pulchra. Eur.
J. Org. Chem. 2014, 2014, 1594–1596. [CrossRef]
43. Killander, D.; Sterner, O. Reagent-Controlled Cyclization—Deprotection Reaction to Yield either Fluorenes or Benzochromenes.
Eur. J. Org. Chem. 2014, 2014, 6507–6512. [CrossRef]
44. Terrazas, P.; Salamanca, E.; Dávila, M.; Manner, S.; Giménez, A.; Sterner, O. SAR:s for the Antiparasitic Plant Metabolite Pulchrol.
1. The Benzyl Alcohol Functionality. Molecules 2020, 25, 3058. [CrossRef]
45. Terrazas, P.; Salamanca, E.; Dávila, M.; Manner, S.; Giménez, A.; Sterner, O. SAR:s for the Antiparasitic Plant Metabolite Pulchrol.
2. B- and C-ring substituents. Molecules 2020, 25, 4510. [CrossRef]
46. Caprioglio, D.; Mattoteia, D.; Minassi, A.; Pollastro, F.; Lopatriello, A.; Munˇoz, E.; Taglialatela-Scafati, O.; Appendino, G. One-Pot
Total Synthesis of Cannabinol via Iodine-Mediated Deconstructive Annulation. Org. Lett. 2019, 21, 6122–6125. [CrossRef]
47. Bilbao-Ramos, P.; Dea-Ayuela, M.A.; Cardenas-Alegría, O. Leishmaniasis in the major endemic region of Plurinational State of
Bolivia: Species identification, phylogeography and drug susceptibility implications. Acta Trop. 2017, 176, 150–161. [CrossRef]
48. Williams, C.; Espinosa, O.A.; Montenegro, H. Hydrosoluble formazan XTT: Its application to natural products drug discovery for
Leishmania. J. Microbiol. Methods 2003, 55, 813–816. [CrossRef] [PubMed]
49. Campos-Buzzi, F.; Fracasso, M.; Clase, B.K.; Ticona, J.C.; Gimenez, A.; Cechinel-Filho, V. Evaluation of antinociceptive effects
of Galipea longiflora alkaloid extract and major alkaloid 2-fenilquinoline. Methods Find. Exp. Clin. Pharmacol. 2010, 32, 707–711.
50. Muelas-Serrano, S.; Nogal-Ruiz, J.; Gomez-Barrio, A. Setting of a colorimetric method to determine the viability of Trypanosoma
cruzi epimastigotes. Parasitol. Res. 2000, 86, 999–1002. [CrossRef]